查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1942760

2026年全球药物洗脱支架市场报告

Drug Eluting Stent Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，药物释放型支架市场经历了显着成长，预计将从2025年的82.6亿美元成长到2026年的89.4亿美元，复合年增长率为8.2%。过去几年的增长可归因于冠状动脉疾病盛行率的上升、经经皮冠状动脉介入治疗（PCI）手术量的增加、文明病相关心血管疾病发病率的上升、心臟导管检查室的扩建以及与裸金属支架相比临床疗效的改善。

预计未来几年药物释放型支架市场规模将强劲成长，2030年将达到117亿美元，复合年增长率（CAGR）为6.9%。预测期内的成长要素包括人口老化、对微创心臟手术需求的增长、对先进支架技术的认知度提高、专科心臟病诊所的扩张以及心血管护理医疗费用支出的增加。预测期内的主要趋势包括可生物降解聚合物支架的日益普及、对无聚合物药物释放型支架的偏好不断增强、其在复杂冠状动脉介入治疗中的应用范围扩大、向长期预防血管再阻塞的转变以及对改进的控制释放的需求不断增长。

冠状动脉疾病（CHD）日益严重的负担预计将推动药物释放型支架市场的未来成长。冠状动脉疾病（CHD）是指冠状动脉因斑块堆积而变窄或阻塞的疾病，可能导致心肌梗塞和胸痛等严重併发症。久坐的生活方式、不良的饮食习惯、人口老化以及人们对该疾病的认知提高，都导致冠状动脉疾病的发生率不断上升。药物释放型支架（DES）透过有效扩张狭窄或阻塞的冠状动脉并释放药物来防止动脉再次血管再阻塞（血管再阻塞），有助于治疗心臟疾病。例如，根据美国政府机构国家生物技术资讯中心（NCBI）的数据，截至2025年8月，预计2025年至2050年间心血管疾病将显着增加，盛行率将上升90.0%，粗死亡率将上升73.4%，粗伤残调整寿命年（DALYs）将上升54.7%。这将导致心血管疾病死亡人数增加，预计到2050年将达到3560万，而2025年为2050万。心臟疾病负担的加重预计将推动药物释放型支架市场的成长。

药物释放型支架市场的主要企业正致力于开发创新产品，例如低轮廓、高柔软性支架，以提高其在复杂冠状动脉解剖结构中的输送性能，并改善患者预后。低轮廓、高柔软性支架是药物释放型支架，其通过血管的阻力更小，柔软性更高，使其能够更轻鬆地穿过狭窄、迂曲和钙化的冠状动脉，同时保持有效的药物输送，从而预防血管再阻塞。例如，2024年5月，总部位于美国的全球医疗保健公司雅培（Abbott Laboratories）在印度推出了XIENCE Sierra依Everolimus洗脱冠状动脉支架系统。 XIENCE Sierra采用新型支架设计，与同类产品相比，具有一流的输送性能和显着降低的通过阻力。它还具有更薄的球囊和优化的MULTI-LINK结构，从而提高了柔软性，同时其高纵向强度确保了支架的稳定性和抗变形能力。此外，宽广的扩张范围使得即使病变部位的血管直径发生变化，也能进行精确治疗，从而使介入性心臟病专家能够更精确、更安全地处理复杂、钙化或难以触及的病变。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球药物洗脱支架市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略契合度评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 主要原料、资源和供应商清单
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章 全球市场趋势与策略

  • 关键技术和未来趋势
    • 生物技术、基因组学和精准医学
    • 工业4.0和智慧製造
    • 数位化、云端运算、巨量资料、网路安全
    • 人工智慧（AI）和自主人工智慧
    • 永续性、气候技术和循环经济
  • 主要趋势
    • 扩大可生物分解聚合物支架的应用
    • 消费者越来越倾向选择不含聚合物的涂药支架
    • 在复杂冠状动脉介入治疗的应用日益增多
    • 过渡到长期预防血管再阻塞
    • 改良型控释控制释放的需求日益增长

第五章 终端用户产业市场分析

  • 医院
  • 专科诊所
  • 心臟导管检查室
  • 门诊心臟护理中心
  • 三级心臟病中心

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及新冠疫情对市场的影响

第七章 全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球药物洗脱支架市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球药物洗脱支架市场规模、比较及成长率分析
  • 全球药物洗脱支架市场表现：规模与成长，2020-2025年
  • 全球药物洗脱支架市场预测：规模与成长，2025-2030年，2035年预测

第八章 全球潜在市场规模（TAM）

第九章 市场细分

  • 副产品
  • 基于聚合物的，不含聚合物的
  • 药物
  • Sirolimus、紫杉醇、佐他莫司、Everolimus、比奥利莫司和其他药物
  • 由鹰架
  • 钴铬合金、铂铬合金、镍钛诺、可生物降解材料及其他支架
  • 透过使用
  • 冠状动脉疾病、週边血管疾病
  • 最终用户
  • 医院、专科诊所
  • 按类型细分：聚合物基
  • 耐久型聚合物药物释放型支架，可生物分解型聚合物药物释放型支架
  • 按类型细分：无聚合物
  • 药物涂层裸金属支架和其他不含聚合物的药物释放型支架

第十章 区域与国家分析

  • 全球药物洗脱支架市场：依地区、绩效及预测划分，2020-2025年、2025-2030年预测、2035年预测
  • 全球药物洗脱支架市场：依国家、表现及预测划分，2020-2025年、2025-2030年预测、2035年预测

第十一章 亚太市场

第十二章：中国市场

第十三章 印度市场

第十四章 日本市场

第十五章：澳洲市场

第十六章 印尼市场

第十七章 韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第二十章：西欧市场

第21章英国市场

第22章 德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章 东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第30章：加拿大市场

第31章 南美洲市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第35章 市场监理与投资环境

第三十六章：竞争格局与公司概况

  • 药物洗脱支架市场：竞争格局及市场占有率（2024年）
  • 药物洗脱支架市场：公司估值矩阵
  • 药物洗脱支架市场：公司概况
    • Abbott Laboratories
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • BIOTRONIK SE & Co KG

第37章：其他领先和创新企业

  • Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis（Cardinal Health）DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

第38章 全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年药物洗脱支架市场：提供新机会的国家
  • 2030年药物洗脱支架市场：充满新机会的细分市场
  • 2030年药物洗脱支架市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第41章附录

简介目录
Product Code: ME3MDESL01_G26Q1

A drug-eluting stent (DES) is a medical device employed in the treatment of coronary artery disease (CAD). It constitutes a small, mesh-like tube typically constructed from metal, which is inserted into narrowed or blocked coronary arteries during a procedure known as percutaneous coronary intervention (PCI) or angioplasty.

The primary product types of drug-eluting stents include polymer-based and polymer-free varieties. Polymer-based drug-eluting stents (DES) are stents coated with a thin polymer layer that encapsulates the drug(s) intended for delivery to the arterial wall. These drugs may include sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, among others, with scaffolds such as cobalt-chromium, platinum-chromium, nitinol, biodegradable materials, and others. They find application in coronary diseases and peripheral vascular disease and are utilized by end-users such as hospitals and specialty clinics.

Tariffs are impacting the drug eluting stent market by increasing costs of imported metal scaffolds, drug compounds, and precision manufacturing equipment used in stent production. These effects are most evident across polymer-based and biodegradable scaffold segments, particularly in regions dependent on cross-border medical device supply chains such as Asia-Pacific and Europe. Higher tariffs have moderately increased procurement costs for hospitals and specialty clinics. At the same time, tariffs are encouraging local manufacturing, supplier diversification, and regional production investments, supporting long-term supply chain resilience.

The drug eluting stent market research report is one of a series of new reports from The Business Research Company that provides drug eluting stent market statistics, including drug eluting stent industry global market size, regional shares, competitors with a drug eluting stent market share, detailed drug eluting stent market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting stent industry. This drug eluting stent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug eluting stent market size has grown strongly in recent years. It will grow from $8.26 billion in 2025 to $8.94 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to increasing prevalence of coronary artery disease, growth in percutaneous coronary intervention procedures, rising incidence of lifestyle-related cardiovascular conditions, expansion of cardiac catheterization labs, improved clinical outcomes compared to bare-metal stents.

The drug eluting stent market size is expected to see strong growth in the next few years. It will grow to $11.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to growing aging population, increasing demand for minimally invasive cardiac treatments, rising awareness of advanced stent technologies, expansion of specialty cardiac clinics, increasing healthcare expenditure on cardiovascular care. Major trends in the forecast period include rising adoption of biodegradable polymer stents, growing preference for polymer-free drug-eluting stents, increasing use in complex coronary interventions, shift toward long-term restenosis prevention, rising demand for improved drug release control.

The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stent market going forward. Coronary heart disease (CHD) is a condition where the coronary arteries become narrowed or blocked due to plaque buildup, potentially leading to severe complications such as a heart attack or chest pain. Coronary heart disease is increasing due to sedentary lifestyles, poor diets, aging populations, and heightened awareness. Drug-eluting stents (DES) benefit coronary heart disease by effectively opening narrowed or blocked coronary arteries and releasing medication that helps prevent re-narrowing (restenosis) of the artery. For example, in August 2025, according to the National Center for Biotechnology Information, a US-based government agency, between 2025 and 2050, cardiovascular disease is projected to rise significantly, with prevalence increasing by 90.0%, crude mortality by 73.4%, and crude DALYs by 54.7%, resulting in an estimated 35.6 million cardiovascular deaths in 2050, up from 20.5 million in 2025. The rising burden of coronary heart disease is expected to propel the growth of the drug-eluting stench market.

Major companies operating in the drug-eluting stent market are focusing on developing innovative products, such as low-profile, high-flexibility stents, to improve deliverability in complex coronary anatomies and enhance patient outcomes. A low-profile, high-flexibility stent is a drug-eluting stent designed with a reduced crossing profile and enhanced flexibility, enabling it to navigate narrow, tortuous, or calcified coronary arteries more easily while maintaining effective drug delivery to prevent restenosis. For example, in May 2024, Abbott Laboratories, a US-based global healthcare company, launched the XIENCE Sierra Everolimus Eluting Coronary Stent System in India. The XIENCE Sierra features a novel stent design that provides best-in-class deliverability with significantly reduced crossing force compared to competitors. It also includes a thinner balloon and an optimized MULTI LINK structure to enhance flexibility, while its high longitudinal strength ensures scaffold stability and resistance to deformation. Additionally, it offers a wide expansion range, allowing precise treatment even when vessel diameters vary along the lesion, enabling interventional cardiologists to address complex, calcified, or difficult-to-reach lesions with improved precision and safety.

In October 2023, Cordis acquired MedAlliance for an undisclosed sum. This acquisition is aimed at furthering Cordis' tradition of cardiovascular innovation and expanding its product portfolio in the coronary and peripheral vascular markets. MedAlliance is a Switzerland-based medical device manufacturer and distributor specializing in drug-eluting stents.

Major companies operating in the drug eluting stent market are Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Terumo Corporation, BIOTRONIK SE & Co KG, Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

North America was the largest region in the drug-eluting stent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting stent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug eluting stent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The drug eluting stent market consists of revenues earned by entities by providing services such as pre-procedural assessment, procedural intervention, intraoperative monitoring, post-procedural care, and patient education. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug eluting stenting market also includes sales of products including guide wires, angioplasty equipment, intravascular imaging systems, hemostasis devices, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Eluting Stent Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses drug eluting stent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug eluting stent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug eluting stent market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Polymer-Based; Polymer-Free
  • 2) By Drug: Sirolimus; Paclitaxel; Zotarolimus; Everolimus; Biolimus; Other Drugs
  • 3) By Scaffold: Cobalt-Chromium; Platinum-Chromium; Nitinol; Biodegradable; Other Scaffolds
  • 4) By Application: Coronary Diseases; Peripheral Vascular Diseases
  • 5) By End-User: Hospitals; Specialty Clinics
  • Subsegments:
  • 1) By Polymer-Based: Durable Polymer Drug-Eluting Stents; Biodegradable Polymer Drug-Eluting Stents
  • 2) By Polymer-Free: Bare-Metal Stents With Drug Coating; Other Polymer-Free Drug-Eluting Stents
  • Companies Mentioned: Abbott Laboratories; Boston Scientific Corporation; Medtronic plc; Terumo Corporation; BIOTRONIK SE & Co KG; Biosensors International Group Ltd; MicroPort Scientific Corporation; Lepu Medical Technology Beijing Co Ltd; Meril Life Sciences Pvt Ltd; Sahajanand Medical Technologies Pvt Ltd; Alvimedica Medical Technologies; Balton Sp z oo; Cordis (Cardinal Health) DES Manufacturing; Shandong JW Medical Systems Ltd; Sino Medical Sciences Technology Inc; STENTYS SA; Relisys Medical Devices Ltd; Translumina GmbH; Eurocor GmbH; Elixir Medical Corporation
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Drug Eluting Stent Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Drug Eluting Stent Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Drug Eluting Stent Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Drug Eluting Stent Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Industry 4.0 & Intelligent Manufacturing
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Biodegradable Polymer Stents
    • 4.2.2 Growing Preference For Polymer-Free Drug-Eluting Stents
    • 4.2.3 Increasing Use In Complex Coronary Interventions
    • 4.2.4 Shift Toward Long-Term Restenosis Prevention
    • 4.2.5 Rising Demand For Improved Drug Release Control

5. Drug Eluting Stent Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Specialty Clinics
  • 5.3 Cardiac Catheterization Laboratories
  • 5.4 Ambulatory Cardiac Care Centers
  • 5.5 Tertiary Care Cardiology Centers

6. Drug Eluting Stent Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Drug Eluting Stent Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Drug Eluting Stent PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Drug Eluting Stent Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Drug Eluting Stent Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Drug Eluting Stent Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Drug Eluting Stent Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Drug Eluting Stent Market Segmentation

  • 9.1. Global Drug Eluting Stent Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Polymer-Based, Polymer-Free
  • 9.2. Global Drug Eluting Stent Market, Segmentation By Drug, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, Other Drugs
  • 9.3. Global Drug Eluting Stent Market, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cobalt-Chromium, Platinum-Chromium, Nitinol, Biodegradable, Other Scaffolds
  • 9.4. Global Drug Eluting Stent Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Coronary Diseases, Peripheral Vascular Diseases
  • 9.5. Global Drug Eluting Stent Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Specialty Clinic
  • 9.6. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Based, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Durable Polymer Drug-Eluting Stents, Biodegradable Polymer Drug-Eluting Stents
  • 9.7. Global Drug Eluting Stent Market, Sub-Segmentation Of Polymer-Free, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Bare-Metal Stents With Drug Coating, Other Polymer-Free Drug-Eluting Stents

10. Drug Eluting Stent Market Regional And Country Analysis

  • 10.1. Global Drug Eluting Stent Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Drug Eluting Stent Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Drug Eluting Stent Market

  • 11.1. Asia-Pacific Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Drug Eluting Stent Market

  • 12.1. China Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Drug Eluting Stent Market

  • 13.1. India Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Drug Eluting Stent Market

  • 14.1. Japan Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Drug Eluting Stent Market

  • 15.1. Australia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Drug Eluting Stent Market

  • 16.1. Indonesia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Drug Eluting Stent Market

  • 17.1. South Korea Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Drug Eluting Stent Market

  • 18.1. Taiwan Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Drug Eluting Stent Market

  • 19.1. South East Asia Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Drug Eluting Stent Market

  • 20.1. Western Europe Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Drug Eluting Stent Market

  • 21.1. UK Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Drug Eluting Stent Market

  • 22.1. Germany Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Drug Eluting Stent Market

  • 23.1. France Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Drug Eluting Stent Market

  • 24.1. Italy Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Drug Eluting Stent Market

  • 25.1. Spain Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Drug Eluting Stent Market

  • 26.1. Eastern Europe Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Drug Eluting Stent Market

  • 27.1. Russia Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Drug Eluting Stent Market

  • 28.1. North America Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Drug Eluting Stent Market

  • 29.1. USA Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Drug Eluting Stent Market

  • 30.1. Canada Drug Eluting Stent Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Drug Eluting Stent Market

  • 31.1. South America Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Drug Eluting Stent Market

  • 32.1. Brazil Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Drug Eluting Stent Market

  • 33.1. Middle East Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Drug Eluting Stent Market

  • 34.1. Africa Drug Eluting Stent Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Drug Eluting Stent Market, Segmentation By Product, Segmentation By Drug, Segmentation By Scaffold, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Drug Eluting Stent Market Regulatory and Investment Landscape

36. Drug Eluting Stent Market Competitive Landscape And Company Profiles

  • 36.1. Drug Eluting Stent Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Drug Eluting Stent Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Drug Eluting Stent Market Company Profiles
    • 36.3.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Terumo Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. BIOTRONIK SE & Co KG Overview, Products and Services, Strategy and Financial Analysis

37. Drug Eluting Stent Market Other Major And Innovative Companies

  • Biosensors International Group Ltd, MicroPort Scientific Corporation, Lepu Medical Technology Beijing Co Ltd, Meril Life Sciences Pvt Ltd, Sahajanand Medical Technologies Pvt Ltd, Alvimedica Medical Technologies, Balton Sp z oo, Cordis (Cardinal Health) DES Manufacturing, Shandong JW Medical Systems Ltd, Sino Medical Sciences Technology Inc, STENTYS SA, Relisys Medical Devices Ltd, Translumina GmbH, Eurocor GmbH, Elixir Medical Corporation

38. Global Drug Eluting Stent Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Drug Eluting Stent Market

40. Drug Eluting Stent Market High Potential Countries, Segments and Strategies

  • 40.1 Drug Eluting Stent Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Drug Eluting Stent Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Drug Eluting Stent Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer